FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Biologics

CBER Updates 2023 Guidance Agenda

CBER issues a revised guidance agenda for 2023 with 13 likely guidances in three categories.

latest-news-card-1
Human Drugs

3 GOP Senators Push FDA on Chinese Cancer Drugs

Republican Sens. Scott, Vance, and Braun criticize FDAs decision to allow the importation of some Chinese-approved cancer drugs to help alleviate the ...

latest-news-card-1
Marketing

Comments on OPDP Quantitative Claims Research

Two stakeholders raise questions about proposed Office of Prescription Drug Promotion research into quantitative claims in direct-to-consumer prescrip...

Medical Devices

FDA Reiterates NuVasive Device Indications

FDA reiterates the indication and instructions for use of the NuVasive Specialized Orthopedics Precice Intramedullary Limb Lengthening system.

latest-news-card-1
Medical Devices

Candela Laser Cleared for Capillary Malformations

FDA clears a Candela 510(k) to expand the labeled indication of its Vbeam Pulsed Dye Laser for use of the 595 nm wavelength to include treating pediat...

latest-news-card-1
Medical Devices

Overject AI Technology for Dental Caries Cleared

FDA clears an Overjet 510(k) to expand the use of its artificial intelligence technology for predicting tooth decay in younger patients.

latest-news-card-1
Human Drugs

Pfizer/OPKO Pediatric Growth Hormone OKd

FDA approves a Pfizer and OPKO Health BLA for Ngenla (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treating pediatric pa...

latest-news-card-1
Human Drugs

Eton Pharma Gets Complete Response Letter

FDA sends Eton Pharmaceuticals a second complete response letter on its NDA for dehydrated alcohol injection for treating methanol poisoning.

latest-news-card-1
Federal Register

Compounded Drug Wholesaling Prohibition Guide

Federal Register notice: FDA makes available a draft guidance entitled Prohibition on Wholesaling Under Section 503B of the Federal Food, Drug, and Co...

latest-news-card-1
Human Drugs

4 Observations in Prisma Health FDA-483

FDA releases the form FDA-483 with four observations issued following an inspection at the Prisma Health outsourcing facility in Simpsonville, SC.